BACKGROUND. Parents of children with juvenile idiopathic arthritis (JIA) are often faced with difficult decisions surrounding the most effective, convenient, safe, and cost-effective treatment for their child. A discrete choice experiment (DCE) was used to determine parents’ preferences for drug treatments and health outcomes in JIA.
METHODS. A questionnaire survey including a DCE was administered to parents of children with JIA. Multinomial logit regression was used to estimate part-worth utilities and willingness-to-pay.
RESULTS. Participation in daily activities was the most important attribute. Parents were willing to pay up to $2,332 for participation without any difficulty (95% CI $1,478, $3,508). Child age, gender, years with JIA, and household income had the greatest impact on preference. Parents’ were willing to pay $2,080 to switch from a drug representing methotrexate to etanercept (95% CI $698, $4,065).
CONCLUSIONS. Parents of children with JIA had the highest maximum willingness-to-pay for drug treatments that improve daily functioning and reduce pain. Cost is a significant factor in the decisions that parents make surrounding the best treatment for a child.